BioSpace News Archive

Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.

Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.

With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provide greater protection against transmission of COVID-19.

CohBar, Inc. is pioneering mitochondrial-based therapies with a candidate in a Phase Ia/Ib clinical trial as a potential treatment for nonalcoholic steatohepatitis (NASH) and obesity, where top-line results are expected later this year.

Amicus Therapeutics announced topline results from its Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease (LOPD). Although the results showed some positive data, it failed to hit the primary endpoint.

A long-running court battle over PCSK9 antibodies between Amgen and Sanofi and Regeneron has come to an end, for now at least.

Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.

It was a busy week for clinical trial announcements and news. Here’s a look.

The U.S. Food and Drug Administration (FDA) has several solid PDUFA dates in the middle of February. Here’s a look.

After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and are now showing positive results from four studies for its newest blindness-fighting treatment.